Progesterone Therapy, Endothelial Function and Cardiovascular Risk Factors: A 3-Month Randomized, Placebo-Controlled Trial in Healthy Early Postmenopausal Women
Figure 4
Changes in Framingham General Cardiovascular System Profile [26] 10-y Risk Score.
These data are from 108 untreated healthy postmenopausal women (1–11 years since their last menstrual flow) in a randomized controlled trial of oral micronized progesterone (300 mg daily, Progesterone; n = 63) or identical placebo (Placebo, n = 45) for treatment of hot flushes/flashes and night sweats. This pair of dot-plots shows women's Framingham General CVS Profile during run-in by assignment to Progesterone or Placebo (left panel) and at the end of 12-weeks of experimental therapy (right panel). None of these differences were statistically significant.